Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement

Trost, Landon; Şerefoğlu, Ege Can; Gökçe, Ahmet; Linder, Brian J.; Sartor, A. Oliver

doi:10.1111/jsm.12036

Cited by 29 publications

(20 citation statements)

References 191 publications

(257 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Authors did not give a conclusion in relation to cancer-related cognitive impairment Trost (2013), USA To review adverse events associated with ADT as well as treatment options…”

Section: Results Amentioning

confidence: 99%

“…Twenty-eight reviews (Ahles & Saykin 2007;Artherholt & Fann 2012;Beauchet 2006;Biegler et al 2009;Chen & Petrylak 2004;Chism & Kunkel 2009;Droz et al 2010;Falci et al 2009;Green et al 2005;Grossmann & Zajac 2011;Gruca et al 2012;Harrington et al 2010;Holzbeierlein 2006;Isbarn et al 2009;Jamadar et al 2012;Janelsins et al 2011;Mitsiades et al 2008;Mohile et al 2009;Mottet et al 2006;Nelson et al 2008;Scherr & Pitts 2003;Sharifi 2005;Trost et al 2013;Tombal 2009;Wefel et al 2004;Wright et al 2006;Ziółkowska et al 2012) described twenty primary studies (Alibhai et al 2010;Almeida et al 2004;Beer et al 2006;Beer et al 2004;Bloomfield & Shilling 2004;Bussiere et al 2005;Cherrier et al 2003;Cherrier et al 2009;DiBlasio et al 2008;Green et al 2002;Green et al 2004;Jenkins et al 2005;Joly et al 2006;Mohile et al 2010;…”

Section: Review Characteristicsunclassified

See 1 more Smart Citation

Cognitive impairment among prostate cancer patients: An overview of reviews

Treanor

Donnelly

2017

Eur J Cancer Care

View full text Add to dashboard Cite

To identify and clarify definitions and methods of measuring cancer‐related cognitive impairment among prostate cancer patients treated with androgen deprivation therapy (ADT) and to assess the incidence and prevalence of cognitive impairment. A systematic review of Medline, EMBASE, PubMed, PsycINFO and CINAHL up to December 2015 was undertaken to identify English‐language reviews. A total of 28 reviews were identified describing 20 primary studies. There were no studies of incidence. Reported prevalence rates varied between 10% and 69%. Cognitive domains impaired by ADT included: verbal memory, visuospatial ability and executive functions. Cognitive impairment was infrequently defined and four definitions were reported. A variety of measures and methods were used to assess cognitive function including neuropsychological tests, self‐report measures and clinical assessments. The finding that, often, one measure was used to assess more than one aspect of cognition is likely to have contributed to imprecise estimates. There is a need to agree a definition of cognitive impairment in the clinical epidemiology of cancer and to standardise the selection of measures in order to aid accurate assessment and fair comparisons across studies regarding the prevalence of cognitive impairment among prostate cancer patients.

show abstract

“…Authors did not give a conclusion in relation to cancer-related cognitive impairment Trost (2013), USA To review adverse events associated with ADT as well as treatment options…”

Section: Results Amentioning

confidence: 99%

Section: Review Characteristicsunclassified

Cognitive impairment among prostate cancer patients: An overview of reviews

Treanor

Donnelly

2017

Eur J Cancer Care

View full text Add to dashboard Cite

show abstract

“…Although exercise has been shown to be important for the prevention and management of cognitive impairment in cancer patients generally (Zimmer et al 2016), various reviews have also associated exercise interventions with improved cognitive function in men treated with ADT (Trost et al 2013, Ahmadi & Daneshmand 2014, Gardner et al 2014, Nguyen et al 2015. However, as shown in Table 3, many of these exercise trials are limited by the use of a generalised quality of life (QoL) questionnaire containing subjective measures of cognitive function, such as the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC-QLQ C30) (Culos-Reed et al 2007, Livingston et al 2011, Oh et al 2012, Cormie et al 2014a, Buffart et al 2015.…”

Section: Effects Of Exercise Training On Cognitive Function In Men Onmentioning

confidence: 99%

Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training

Mundell¹,

Daly²,

Macpherson³

2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is an effective and widely prescribed treatment for prostate cancer (PCa), but it is associated with multiple treatment-induced adverse effects that impact on various musculoskeletal and cardiometabolic health outcomes. Emerging research has shown that ADT is also associated with cognitive impairment, which has been linked to a loss of independence, increased falls and fracture risk and greater use of medical services. The aim of this review is to outline the evidence related to the effect of ADT use on cognitive function, and propose a role for exercise training as part of usual care to prevent and/or manage cognitive impairments for PCa survivors on ADT. The following results have been obtained from this study. ADT has been shown to adversely affect specific cognitive domains, particularly verbal memory, visuomotor function, attention and executive function. However, current clinical guidelines do not recommend routine assessment of cognitive function in these men. No studies have examined whether exercise training can preserve or improve cognitive function in these men, but in healthy adults', multimodal exercise training incorporating aerobic training, progressive resistance training (PRT) and challenging motor control exercises have the potential to attenuate cognitive decline. In conclusion, as treatment with ADT for men with PCa has been associated with a decline in cognition, it is recommended that cognitive function be routinely monitored in these men and that regular exercise training be prescribed to preserve (or improve) cognitive function. Assessment of cognition and individualised exercise training should be considered in the usual treatment plan of PCa patients receiving ADT.

show abstract

“…

The recent comprehensive review by Trost et al highlighting the impact of androgen deprivation therapy (ADT) with luteinising hormone-releasing hormone agonists (LHRHa) on quality of life (QoL) of prostate cancer survivors is timely in view of increasing usage and accumulating evidence of its harms [1]. LHRHa were developed because oral estrogen, a major option for treating prostate cancer through ADT in the second half of the 20th century, was discontinued due to its excessive cardiovascular (CVS) mortality [2].

…”

mentioning

confidence: 99%

“…LHRHa were developed because oral estrogen, a major option for treating prostate cancer through ADT in the second half of the 20th century, was discontinued due to its excessive cardiovascular (CVS) mortality [2]. The authors report a wide range of adverse events with LHRHa and include advice for monitoring and management options [1]. That contemporary ADT using LHRHa suppresses endogenous testosterone levels (by about 95%) is well known but that estrogen is derived from testosterone via aromatization and endogenous estrogen levels are consequently also reduced (by about 80%) is far less appreciated [3,4].…”

mentioning

confidence: 99%